Clinical trial
A Study to Investigate Mepolizumab in the Treatment of Eosinophilic…
NCT02020889 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT02020889 |
|---|---|
| Title | A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis |
| Official title | A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Churg-Strauss Syndrome |
| Intervention type | Biological, Drug |
| Interventions | Mepolizumab, Placebo |
| Enrollment | 136 |
| Start date | Feb 5, 2014 |
| Primary completion | Sep 5, 2016 |
| Completion | Sep 5, 2016 |
| First posted | Dec 25, 2013 |
| Last update posted | Jan 31, 2018 |
| Countries | Belgium, Canada, France, Germany, Italy, Japan, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: